Abstract | PURPOSE: MATERIALS AND METHODS: A total of 19 rats were evaluated, divided into 2 groups. Group 1 (n = 10) was examined using gadobutrol and gadopentetate dimeglumine and group 2 (n = 9) was examined using gadobutrol and gadoterate meglumine. The time between the intraindividual injections was at least 24 hours and contrast agent injections were performed in a randomized order. All agents were applied at a dose of 0.1 mmol/kg body weight.Image acquisition was performed using a T1-weighted 2D TSE technique (repetition time/echo time (TE) 500/16, FA 180 degrees) with an acquisition time of 1:47 minutes:seconds. At a field-of-view of 75 x 75 mm2 and a matrix size of 320 x 320, a voxel size of 0.2 x 0.2 x 2.0 mm3 was achieved. Data acquisition was performed before and at 5 consecutive time points every 2 minutes after contrast agent injection. Signal-to-noise ratios (SNRs) of tumor and normal contralateral brain as well as contrast-to-noise ratio (CNR) measurements were performed using region of interest analysis. RESULTS: The increase in tumor contrast enhancement, ranged between 19.6% and 35.9% for gadobutrol versus gadopentetate dimeglumine (group 1) and between 23.2% and 27.8% for gadobutrol versus gadoterate meglumine (group 2). Overall, CNR was statistically significantly higher for gadobutrol in both groups (P < 0.0001). CNR values for gadobutrol were 25.5 +/- 8.2 in group 1 and 27.1 +/- 8.3 in group 2 with respective CNR values for gadopentetate dimeglumine of 18.6 +/- 5.6 and gadoterate meglumine of 19.2 +/- 5.3. At each acquired time point mean values of tumor SNR were higher for gadobutrol (group 1: SNR(mean) range from 78.7-89.1 vs. 74.3-80.8; group 2: SNR(mean) range from 79.9-88.9 vs. 74.2-80.8). Tumor SNR was statistically significant different at all measured time points in group 2 (P < 0.05). In group 1, the difference of tumor SNR was also statistically significant for the gadobutrol/ gadopentetate dimeglumine comparison (P < 0.05) with exception of time point at 9 minutes postcontrast (P = 0.07). CONCLUSION:
|
Authors | Ulrike I Attenberger, Val M Runge, Carney B Jackson, Shannon Baumann, Krista Birkemeier, Henrik J Michaely, Stefan O Schoenberg, Maximilian F Reiser, Bernd J Wintersperger |
Journal | Investigative radiology
(Invest Radiol)
Vol. 44
Issue 5
Pg. 251-6
(May 2009)
ISSN: 1536-0210 [Electronic] United States |
PMID | 19550376
(Publication Type: Comparative Study, Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Chelating Agents
- Contrast Media
- Organometallic Compounds
- gadobutrol
- Meglumine
- Gadolinium DTPA
- gadoterate meglumine
|
Topics |
- Animals
- Brain Neoplasms
(diagnosis)
- Chelating Agents
- Contrast Media
(administration & dosage)
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Gadolinium DTPA
(administration & dosage)
- Humans
- Image Enhancement
(methods)
- Meglumine
(administration & dosage)
- Organometallic Compounds
(administration & dosage)
- Rats
- Rats, Inbred F344
- Reproducibility of Results
- Sensitivity and Specificity
|